Objective Parkinson disease is characterized by motor and nonmotor symptoms, reduced
striatal dopamine signaling, and loss of dopamine neurons in the substantia nigra. It is now …

Background It has been hypothesized that the pathology of Parkinson's disease (PD)
primarily affects presynaptic terminals and spreads trans‐synaptically. Objectives The main …

ABSTRACT Background Patients with Parkinson's disease (PD) often develop dementia, but
the underlying substrate is incompletely understood. Generalized synaptic degeneration …

The type-2 vesicular monoamine transporter (VMAT2) might serve as an objective biomarker
of Parkinson disease (PD) severity. Thirty-one subjects with early-stage PD and 75 normal …

Parkinson's disease (PD) is a progressive neurodegenerative disease that impairs
movement as well as causing multiple other symptoms such as autonomic dysfunction, rapid …

There is mounting evidence that Parkinson's disease (PD) and Alzheimer's disease (AD)
share neuropathological hallmarks, while similar types of biomarkers are being applied to …

A progressive loss of dopamine neurons in the substantia nigra (SN) is considered the main
feature of idiopathic Parkinson's disease (PD). Recent neuropathological evidence however …

Parkinson's disease is a heterogeneous disorder with multiple factors contributing to
disease initiation and progression. Using serial, multi-tracer positron emission tomography …

Advances in molecular and structural and functional neuroimaging are rapidly expanding
the complexity of neurobiological understanding of Parkinson's disease (PD). This review …

Objective: To examine possible associations between in vivo brain dopamine transporter
SPECT imaging and substantia nigra pars compacta (SNc) neuronal survival in Parkinson …